PMV Pharmaceuticals (PMVP) Share-based Compensation (2019 - 2026)
PMV Pharmaceuticals' (PMVP) quarterly Share-based Compensation came in at $1.4 million in Q1 2026, down 7.69% YoY from $1.5 million in Q1 2025, and up 1.98% on a QoQ basis from $1.4 million in Q4 2025.
PMV Pharmaceuticals (PMVP) Share-based Compensation (2019 - 2026) Analysis & Trends
PMV Pharmaceuticals (PMVP) has 8 years of Share-based Compensation data on file, last reported at $1.4 million in Q1 2026.
- Quarterly Share-based Compensation fell 7.69% year-over-year to $1.4 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $5.6 million (down 27.31% YoY) and the FY2025 annual result came in at $11.2 million, down 16.75% from the prior year.
- Share-based Compensation grew to $1.4 million in Q1 2026, from $1.4 million in the prior quarter.
- In the past five years, Share-based Compensation ranged from a high of $13.9 million in Q2 2025 to a low of $1.3 million in Q4 2024.
- A 5-year average of $3.0 million and a median of $2.5 million in 2022 frame the typical range for Share-based Compensation.
- Annual changes were most pronounced in 2024 — Share-based Compensation plunged 57.15% — and 2025, when it jumped 401.12%.
- Tracing PMVP's Share-based Compensation over 5 years: stood at $3.1 million in 2022, then decreased by 2.82% to $3.0 million in 2023, then plunged by 57.15% to $1.3 million in 2024, then advanced by 7.4% to $1.4 million in 2025, then rose by 1.98% to $1.4 million in 2026.
- The last three Share-based Compensation figures came in at $1.4 million (Q1 2026), $1.4 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Stock Comp. (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 140.22 Bn | 132.37 Bn | 2.84 Bn | 108.10 Mn |
| 2 | Regeneron Pharmaceuticals | 86.29 Bn | 78.30 Bn | 3.93 Bn | 243.00 Mn |
| 3 | Argenx Se | 65.17 Bn | 59.98 Bn | 1.37 Bn | - |
| 4 | Moderna | 61.38 Bn | 56.24 Bn | 52.00 Mn | 120.00 Mn |
| 5 | BeOne Medicines | 42.18 Bn | 37.09 Bn | 1.53 Bn | 137.41 Mn |
| 6 | Alnylam Pharmaceuticals | 30.99 Bn | 27.68 Bn | 992.69 Mn | 86.63 Mn |
| 7 | BioNTech SE | 28.45 Bn | 10.05 Bn | 668.28 Mn | 28.05 Mn |
| 8 | Insmed | 27.47 Bn | 26.31 Bn | 358.27 Mn | 41.25 Mn |
| 9 | Royalty Pharma | 27.27 Bn | 26.43 Bn | - | - |
| 10 | PMV Pharmaceuticals | 70.74 Mn | -8.69 Mn | - | 12.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 1.39 Mn |
| Mar 31, 2026 | 1.39 Mn |
| Dec 31, 2025 | 1.37 Mn |
| Dec 31, 2025 | 1.37 Mn |
| Sep 30, 2025 | 1.38 Mn |
| Sep 30, 2025 | 1.38 Mn |
| Jun 30, 2025 | 13.87 Mn |
| Jun 30, 2025 | 13.87 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Mar 31, 2025 | 1.51 Mn |
| Dec 31, 2024 | 1.27 Mn |
| Dec 31, 2024 | 1.27 Mn |
| Sep 30, 2024 | 2.22 Mn |
| Sep 30, 2024 | 2.22 Mn |
| Jun 30, 2024 | 2.77 Mn |
| Jun 30, 2024 | 2.77 Mn |
| Mar 31, 2024 | 2.61 Mn |
| Mar 31, 2024 | 2.61 Mn |
| Dec 31, 2023 | 2.97 Mn |
| Dec 31, 2023 | 2.97 Mn |